Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial

Harry H. Yoon, J. C. Bendell, F. S. Braiteh, I. Firdaus, P. A. Philip, A. L. Cohn, N. Lewis, D. M. Anderson, E. Arrowsmith, J. D. Schwartz, L. Gao, Y. Hsu, Y. Xu, D. Ferry, S. R. Alberts, Z. A. Wainberg

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Fingerprint Dive into the research topics of 'Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences